FIA
TAK icon

FNY Investment Advisers’s Takeda Pharmaceutical TAK Stock Holding History

FNY Investment Advisers’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-60
Closed -$1K – 947
2018
Q4 		$1K Buy
+60
New +$1.01K ﹤0.01% 634

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

FNY Investment Advisers's TAK Position: Q2 2025 in Review

FNY Investment Advisers sold out of Takeda Pharmaceutical (TAK) in Q2 2025, closing a stake of 2,500 shares — an estimated $37K sold.

FNY Investment Advisers first reported a position in TAK in Q1 2019 and held it in 15 quarters. The position peaked at $4.76M in Q3 2021. 316 funds tracked by Wall St. Rank hold TAK as of Q2 2025.

  • FNY Investment Advisers reported no remaining Takeda Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 2,500 Takeda Pharmaceutical shares in Q2 2025, an estimated $37K.
  • FNY Investment Advisers first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 15 quarters.
  • FNY Investment Advisers's Takeda Pharmaceutical position peaked at $4.76M in Q3 2021.
  • 316 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2025.

Based on FNY Investment Advisers's 13F filing for Q2 2025, filed 30 Jul 2025.